JP2017533707A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533707A5
JP2017533707A5 JP2017523289A JP2017523289A JP2017533707A5 JP 2017533707 A5 JP2017533707 A5 JP 2017533707A5 JP 2017523289 A JP2017523289 A JP 2017523289A JP 2017523289 A JP2017523289 A JP 2017523289A JP 2017533707 A5 JP2017533707 A5 JP 2017533707A5
Authority
JP
Japan
Prior art keywords
cells
population
cancer
disease
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017523289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533707A (ja
JP6884697B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/058228 external-priority patent/WO2016069993A1/en
Publication of JP2017533707A publication Critical patent/JP2017533707A/ja
Publication of JP2017533707A5 publication Critical patent/JP2017533707A5/ja
Application granted granted Critical
Publication of JP6884697B2 publication Critical patent/JP6884697B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017523289A 2014-10-31 2015-10-30 T細胞を刺激および拡大する組成物および方法 Active JP6884697B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073268P 2014-10-31 2014-10-31
US62/073,268 2014-10-31
PCT/US2015/058228 WO2016069993A1 (en) 2014-10-31 2015-10-30 Compositions and methods of stimulating and expanding t cells

Publications (3)

Publication Number Publication Date
JP2017533707A JP2017533707A (ja) 2017-11-16
JP2017533707A5 true JP2017533707A5 (enExample) 2018-12-06
JP6884697B2 JP6884697B2 (ja) 2021-06-09

Family

ID=55858377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017523289A Active JP6884697B2 (ja) 2014-10-31 2015-10-30 T細胞を刺激および拡大する組成物および方法

Country Status (9)

Country Link
US (2) US11471487B2 (enExample)
EP (1) EP3217989B1 (enExample)
JP (1) JP6884697B2 (enExample)
KR (3) KR20230141922A (enExample)
CN (1) CN107106609A (enExample)
AU (1) AU2015339106B2 (enExample)
CA (1) CA2966035A1 (enExample)
ES (1) ES2910227T3 (enExample)
WO (1) WO2016069993A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3575319A4 (en) * 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. BIFUNCTIONAL MOLECULE AND USE OF IT
US11535666B2 (en) 2016-12-30 2022-12-27 Cytocares (Shanghai) Inc. Trifunctional molecule and application thereof
EP3633029A4 (en) * 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
KR102546681B1 (ko) 2017-09-01 2023-06-22 론차 콜로그네 게엠베하 엔드-투-엔드 세포 요법의 자동화
CA3113125A1 (en) 2018-09-28 2020-04-02 Octane Biotech Inc. Magnetic separation
JP7179986B2 (ja) 2018-11-14 2022-11-29 グリーン クロス ラボ セル コーポレーション 形質転換されたt細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法
JP7598864B2 (ja) 2018-12-21 2024-12-12 ロンザ ウォーカーズヴィル,インコーポレーテッド ウイルスベクターの自動産生方法
EP3898932A4 (en) 2018-12-21 2022-08-03 Octane Biotech Inc. CAROUSEL FOR MODULAR BIOLOGICAL PRODUCTION UNITS
SG11202108473XA (en) 2019-02-08 2021-09-29 Lonza Walkersville Inc Cell concentration methods and devices for use in automated bioreactors
EP4048773A4 (en) 2019-10-24 2024-01-03 Octane Biotech Inc. CELL CULTURE CHAMBER WITH IMPROVED CELL CONTACT SURFACES
JP2023501443A (ja) 2019-11-11 2023-01-18 ロンザ ウォーカーズヴィル,インコーポレーテッド 自動化された細胞処理のための品質制御方法
WO2021108543A1 (en) * 2019-11-27 2021-06-03 The Trustees Of The University Of Pennsylvania Anti-cd3 scfv and cytokine producing artificial antigen presenting cells
CN114606263B (zh) * 2022-05-11 2022-09-06 上海优替济生生物医药有限公司 分离的核酸分子及其用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
DE69433970T2 (de) 1993-08-10 2005-08-11 W.L. Gore & Associates, Inc., Newark Zelleinkapselungsvorrichtung
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5626561A (en) 1995-06-07 1997-05-06 Gore Hybrid Technologies, Inc. Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
JPH10503964A (ja) 1995-06-07 1998-04-14 ゴア ハイブリッド テクノロジーズ,インコーポレイティド 治療用デバイスのための移植可能な閉じ込め装置並びにその中にそのデバイスを装填及び再装填する方法
AU6854696A (en) 1995-09-22 1997-04-09 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
WO2001066149A2 (en) 2000-03-03 2001-09-13 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20040014645A1 (en) 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20050070841A1 (en) 2002-07-04 2005-03-31 Inovio As Electroporation device and injection apparatus
AU2005250408B2 (en) * 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CN101370927A (zh) 2005-12-07 2009-02-18 基因特伦尼克斯公司 可变容积电穿孔室以及其方法
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012024203A1 (en) * 2010-08-18 2012-02-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of identifying central memory t cells and obtaining antigen-specific t cell populations
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CN104395344B (zh) 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
US10316289B2 (en) * 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
US10117896B2 (en) * 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors

Similar Documents

Publication Publication Date Title
JP2017535261A5 (enExample)
JP2017533706A5 (enExample)
JP2021058196A5 (enExample)
Zhang et al. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
Moscarelli et al. The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells
Bi et al. NK cell exhaustion
Tarazona et al. Current progress in NK cell biology and NK cell-based cancer immunotherapy
Putnam et al. Clinical grade manufacturing of human alloantigen‐reactive regulatory T cells for use in transplantation
JP2018504910A5 (enExample)
Wang et al. Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges
MX2023001962A (es) Composiciones anti-cd28.
JP2018533625A5 (enExample)
JP2019532625A5 (enExample)
WO2018081789A8 (en) Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
JP2019500894A5 (enExample)
IL259120A (en) Her2-targeted antigen chimeric receptors2
JP2014533928A5 (enExample)
FI3102609T3 (fi) Menetelmiä b-solukasvaimien ja muiden syöpien hoidossa käyttökelpoisten autologisten t-solujen ja niiden koostumusten valmistamiseksi
JP2016539929A5 (enExample)
WO2019204462A3 (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
CN118421557A (zh) 选择性扩增γδT细胞群的方法及其组合物
JP2018500006A5 (enExample)
IL292650A (en) Chimeric antigen receptor T cells target il13ra2
ES2910227T3 (es) Composición y métodos para la estimulación y expansión de células T
JP2016520074A5 (enExample)